Login
Open Demat Account
Open Demat A/C
Offerings
+
Research
Markets+
Talking Finance+
Support+
Media+
Partner Us+
Trade LoginReports LoginIFD Partner Login
Demo
Close Language Tab
Locate us
Languages
  • Home
  • Company Information
  • Strides Pharma Science Ltd
S
Strides Pharma Science Ltd Pharmaceuticals
₹ 945.35 -9.20 (-0.96%)
  • NSE
  • BSE

Overview

  • BSE Code 532531
  • NSE Symbol STAR
  • ISIN Demat INE939A01011
  • Book Value (₹) 346.42
  • Face Value (₹) 10.00
  • Market Cap (₹ Cr.) 8,127.83
  • P/E (TTM) 2.82
  • EPS (TTM) 313.18
  • Div Yield (%) 0.45

Performance

Today’s Low 924.30
Today’s High 959.85

945.35
52W Low 435.11
52W High 972.00

945.35
Open 956.40
Prev. Close 954.55
Volume 18,69,895.00

Corporate Actions

Strides Pharma Science Limited - General Updates
Apr 03, 2025

Intimation for change in details of Key Managerial Personnel for determining materiality of events or information and making disclosure to Stock Exchanges under Regulation 30 of SEBI Listing Regulations effective April 5, 2025

About Strides Pharma Science Ltd

History

Strides Pharma Science Ltd came into existence as, originally under the name 'Strides Arcolab Ltd', on June 28th, 1990. In 2002-03, the company signed an MoU with Ribbon SRL Italy to set up a joint venture to manufacture and market Cephalosporin formulations for regulated markets. The company transferred its Contract Research and Manufacturing Division (CRAM) to the wholly owned subsidiary, Strides Research & Specialty Chemicals Ltd, effective from April 1, 2002. In 2005, the company established its new technology centre named STAR-Strides Technology and Research. They also expanded their Anti TB Facility at KRS Gardens, Bengaluru. In 2008, the company completed a series of divestments and acquisitions and rearranged its business into 3 specific business segments, namely Manufacturing and R&D, International Front-ended Business-Generics and Brands and Nutraceuticals Business. In April 2009, they announced a major reorganization of their business whereby they split their operations into 3 separate entities, namely Specialty Pharmaceuticals, Pharmaceuticals & R&D. In December 2012, the company with its subsidiary Agila Specialties Private Ltd collaborated with Eli Lilly to expand the delivery of its cancer medicines in emerging markets. As a part of this arrangement, Lilly in-licensed a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila Specialties, the specialities division of Strides.  In FY 2018, the company exited from the India Brand Business. In 2018-19, the R&D operations of the company remained on track with 21 ANDA filings as against the 20-25 ANDA filings planned for the year. The company also received 15 product approvals in FY 2019. This included the PARA IV approvals for Cinacalcet and Milnacipran Hydrochloride.

Business Segments

As per accounting terms, the company has two business segments reported, i.e. pharmaceutical and bio-pharmaceutical businesses. In terms of the diseases cured, the company’s institutional business is divided into the following categories:
  1. AIDS- The core priority of Strides is on the production and supply of newer anti-retroviral drugs that are difficult to manufacture, including pediatric dispersible formulations, new fixed-dose molecules which Strides accesses through license agreements with Gilead, Vive Healthcare, MPP, among others.
  2. TB or Tuberculosis- Strides has its own state-of-the-art anti-TB drug facility formulating the second-line TB drug.
  3. Malaria- Strides has begun the supply of WHO Pre-Qualified Artemether and Lumefantrine (AL) Tablets, and also AL Dispersible tablets for pediatric use. It has ERP approval for AL 80/480 and Artesunate Suppositories caps.
  4. Hepatitis- Strides has launched “Sofosbuvir and it’s combination drugs” in Africa, South East Asia, CIS and Latam countries for Hepatitis C treatment. This represents a paradigm shift in the existing Hepatitis C cure.
Subsidiaries As of March 31, 2023, the company has 43 subsidiaries, including:
  1. Altima Innovations Inc.- It is a wholly owned subsidiary engaged in trading in pharmaceutical products in the USA.
  2. Generic Partners UK Ltd.- It is a wholly owned subsidiary that supplies and distributes generic pharmaceutical products in the UK.
  3. Pharmapar Inc.- It is a wholly owned subsidiary that trades in pharmaceutical products in Canada.
  4. Strides Pharma Global (UK) Ltd.- It is an Investment Holding organization in the UK that is 100% owned by Strides Pharma Science.

Key Personnel

Mr Arun Kumar, Executive Chairperson and Managing Director Mr Kumar is the Company’s Founder and also the Promoter Director. He is a first-generation entrepreneur with an impressive track record. He founded the company in 1990 and has since led it in establishing a global reputation along with a differentiated business model.

Corporate Actions

The company has not performed any major corporate actions in the recent past. Mergers and Acquisitions
  • In January 2020, the Board of Directors of the organization allowed the merger of its wholly-owned subsidiary, Vivimed Life Sciences Pvt Ltd (Vivimed) into the Company.
  • In September 2019, Strides Pharma Global Pte. Limited (SPG), a step-down subsidiary in Singapore, gained complete control of a 70% equity stake in Fairmed Healthcare AG (Fairmed), a Switzerland-based generic pharma organization.
  • In FY 2016, the organization gained complete control of the erstwhile Ranbaxy's Solus' and Solus Care' divisions which were operating in the Central Nervous System (CNS) segment in India from Sun Pharmaceuticals Limited.
Founded: 1990
Chairman: Arun Kumar
Managing Director: Arun Kumar
Address: No 201 Devavrata Sector 17, Vashi, Navi Mumbai, Maharashtra, 400703,
HO Tel: 91-80-67840738/000